Experimental Hematology
Volume 35, Issue 5 , Pages 702-711 , May 2007

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules

Received 19 October 2006 ,Revised 19 January 2007 ,Accepted 29 January 2007.

References 

  1. Barbui T, Finazzi G, Barosi G. Chronic myeloid disorders, excluding CML. In:  Degos L,  Linch DC,  Löwenberg B editor. Textbook of Malignant Hematology. London: Martin Dunitz Ltd.; 1999;p. 847–869
  2. Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythemia vera and essential thrombocythemia. Br J Haematol. 2005;128:275–290
  3. Gruppo Italiano Studio Policitemia (GISP) . Polycythemia vera: the natural history of 1213 patients followed over 20 years. Ann Intern Med. 1995;123:656–664
  4. Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets. 2004;15:67–84
  5. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;15:2446–2452
  6. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;15:2310–2313
  7. Harrison NH. Platelets and thrombosis in myeloproliferative disorders. Hematology. 2005;409–415
  8. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol. 2005;42:239–247
  9. Jensen MK, Brown PN, Lund BV, et al. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66:143–151
  10. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2002;108:139–145
  11. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261–4266
  12. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523–530
  13. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  14. Kralovics R, Passamonti F, Buser AS, et al. A gain-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790
  15. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148
  16. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397
  17. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–1953
  18. Wolanskkyj AP, Schwagner SM, McClure RF, Tefferi A. Essential thrombocythemia beyond the first decade: expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proc. 2006;81:159–166
  19. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169–175
  20. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676–3682
  21. Wagner C, Iking-Konert C, Hug F, et al. Cellular inflammatory response to persistent localized Staphylococcus aureus infection: phenotypical and functional characterization of polymorphonuclear neutrophils (PMN). Clin Exp Immunol. 2006;143:70–77
  22. Maugeri N, Donati MB, de Gaetano G, Cerletti C. Formation of mixed platelet-PMN leukocyte aggregates in the platelet function analyzer (PFA-100) device. Thromb Haemost. 2007;97:156–157
  23. Cesar JM, de Miguel D, Garcia Avello A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol. 2005;123:772–777
  24. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004;24:1015–1022
  25. Muller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. 2003;17:476–478
  26. Camera M, Frigerio M, Toschi V, et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol. 2003;23:1690–1696
  27. Siddiqui FA, Desai H, Amirkhosravi A, Amaya M, Francis JL. The presence and release of tissue factor from human platelets. Platelets. 2002;13:247–253
  28. Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110:116–124
  29. André P. P-selectin in haemostasis. Br J Haematol. 2004;126:298–306
  30. Furie B, Furie BC. Role of platelet P-selectin and microparticles PSGL-1 in thrombus formation. Trends Mol Med. 2004;10:171–178
  31. Polgar J, Matuskova J, Wagner DD. Links The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005;3:1590–1596
  32. Mazzucato M, De Marco L, De Angelis V, De Roia D, Bizzaro N, Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol. 1989;73:369–374
  33. Thibert V, Bellucci S, Cristofari M, Gluckman E, Legrand C. Increased platelet CD36 constitutes a common marker in myeloproliferative disorders. Br J Haematol. 1995;91:618–624
  34. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197:1585–1598
  35. Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38:1075–1089
  36. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96:170–175
  37. Barnard MR, Linden MD, Frelinger AL, et al. Links Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost. 2005;3:2563–2570
  38. Nemerson Y. Tissue factor in neutrophils. Thromb Haemost. 2000;83:802
  39. Nakamura S, Imamura T, Okamoto K. Tissue factor in neutrophils: yes. J Thromb Haemost. 2004;2:214–217
  40. Osterud B. Tissue factor in neutrophils: no. J Thromb Haemost. 2004;2:218–220
  41. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?. J Thromb Haemost. 2006;4:2593–2598
  42. Maugeri N, Brambilla M, Camera M, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost. 2006;4:1323–1330
  43. Chong AY, Blann AD, Lip GY. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM. 2003;96:253–267

PII: S0301-472X(07)00097-5

doi: 10.1016/j.exphem.2007.01.053

Experimental Hematology
Volume 35, Issue 5 , Pages 702-711 , May 2007

Article Tools

* Image Usage & Resolution